A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00816361 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

MedImmune LLC